Semaglutide self-administration linked to spontaneous pneumomediastinum in 26-year-old woman
Background
Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) like semaglutide are widely used for type 2 diabetes and weight loss. While known for gastrointestinal side effects such as nausea and vomiting, these are typically considered harmless. However, rare but serious complications can arise, particularly with unsupervised use. This case highlights a critical gap in understanding the full spectrum of potential adverse events, specifically the rare occurrence of spontaneous pneumomediastinum (SPM), which can mimic life-threatening conditions like Boerhaave's syndrome.
Study Design
This case report details a 26-year-old woman who presented with acute symptoms after self-administering semaglutide purchased online for weight loss. The patient reported vomiting, chest and neck pain, and progressive facial swelling. Diagnostic imaging, including unspecified scans, was performed to assess the extent of her condition. An oesophago-gastro-duodenoscopy was also conducted to definitively rule out oesophageal perforation, a critical differential diagnosis for her symptoms. The patient's clinical course and management were then observed.
Results
The patient presented with acute symptoms including vomiting, chest and neck pain, and progressive facial swelling. Imaging studies revealed extensive pneumomediastinum and cervicothoracic emphysema, indicating air leakage into the mediastinum and surrounding soft tissues. An oesophago-gastro-duodenoscopy was performed to investigate potential oesophageal perforation, but it showed no abnormalities, effectively ruling out Boerhaave's syndrome. The patient was managed conservatively, meaning no surgical intervention was required, and experienced spontaneous recovery. This outcome underscores the importance of accurate diagnosis to differentiate SPM from more severe conditions. The direct link to semaglutide use, particularly self-administered, suggests a potential, albeit rare, adverse event pathway. The abstract does not provide specific numerical data such as doses, frequencies, or statistical p-values, as is typical for a single case report. The key finding was the presence of air in the mediastinum without an obvious source of perforation.
Imaging revealed extensive pneumomediastinum and cervicothoracic emphysema.
Key Findings
- A 26-year-old woman developed spontaneous pneumomediastinum (SPM) after self-administering semaglutide.
- Patient presented with vomiting, chest and neck pain, and progressive facial swelling.
- Imaging confirmed extensive pneumomediastinum and cervicothoracic emphysema.
- Oesophago-gastro-duodenoscopy ruled out oesophageal perforation, distinguishing SPM from Boerhaave's syndrome.
- The patient recovered spontaneously with conservative management.
Why It Matters
This case report significantly expands the known safety profile of semaglutide, highlighting a rare but serious potential complication: spontaneous pneumomediastinum. For peptide users and biohackers, this underscores the critical risks associated with unsupervised use of injectable weight-loss medications, especially those obtained outside regulated medical channels. Clinicians must be aware of SPM as a differential diagnosis in patients presenting with chest pain and vomiting while on GLP-1 RA therapy, even without clear signs of oesophageal injury. Patient education on proper administration and potential adverse effects is paramount, emphasizing the need for medical supervision. This finding doesn't change current dosing protocols but rather reinforces the necessity of adherence to prescribed medical oversight to mitigate severe, unexpected outcomes.
semaglutide
pneumomediastinum
case report
adverse event
unsupervised use
glp-1 agonist